Previous studies have investigated the efficacy of INC280 (a c-MET inhibitor) in combination with gefitinib in treating NSCLC c-MET-positive patients with EGFR-TKI resistance, which resulted in an ORR of 29% and a DCR of 73%; the mPFS was 5.6 months [33]. Here, EGFR is linked to non-small cell lung carcinoma.